Dr. Kena Swanson is Vice President of Viral Vaccines at Pfizer Vaccine Research and Development. She leads a team focused on novel vaccine candidates, leveraging innovative vaccine platforms from preclinical discovery to late-stage clinical development. She is responsible for vaccine programs including Respiratory Syncytial Virus (RSV) and COVID-19.
Pfizer’s RSV vaccine candidate is in late-stage development for two indications aiming to address where the major RSV disease burden resides – an older adult vaccine candidate and a maternal vaccine candidate for the protection of infants.
The Pfizer-BioNTech COVID-19 vaccine program was initiated in early 2020, which led to an emergency use authorization in nine months and vaccine licensure in the United States in August 2021. The licensed vaccine, Comirnaty™, is now used in countries across the globe.
Dr. Swanson received her PhD in microbiology and immunology from Indiana University School of Medicine and completed her postdoctoral fellowship at NIH/NIAID Rocky Mountain Laboratories in Hamilton, MT prior to joining industry.
Pfizer’s RSV vaccine candidate is in late-stage development for two indications aiming to address where the major RSV disease burden resides – an older adult vaccine candidate and a maternal vaccine candidate for the protection of infants.
The Pfizer-BioNTech COVID-19 vaccine program was initiated in early 2020, which led to an emergency use authorization in nine months and vaccine licensure in the United States in August 2021. The licensed vaccine, Comirnaty™, is now used in countries across the globe.
Dr. Swanson received her PhD in microbiology and immunology from Indiana University School of Medicine and completed her postdoctoral fellowship at NIH/NIAID Rocky Mountain Laboratories in Hamilton, MT prior to joining industry.
Speaking In
3:00 PM - 4:00 PM
Wednesday, June 7
